Revenue grew 6% at CER in H1 2026, driven by Oncology and Rare Disease, offsetting Farxiga headwinds. Core EPS rose 11%, with strong pipeline progress and 30 major approvals. FY 2026 guidance is reaffirmed for mid- to high single-digit revenue growth and low double-digit Core EPS growth.Original do…
Revenue grew 6% at CER in H1 2026, driven by Oncology and Rare Disease, offsetting Farxiga headwinds. Core EPS rose 11%, with strong pipeline progress and 30 major approvals. FY 2026 guidance is reaffirmed for mid- to high single-digit revenue growth and low double-digit Core EPS growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
